STAT November 21, 2019
Rebecca Robbins

CAMBRIDGE, Mass. — Gene therapy pioneer Dr. James Wilson is disappointed by the progress in his field — and expects current therapies and technologies to be soon surpassed by new approaches.

“In five years, when we look back on the way we’re executing on gene therapy now, we’re going to realize that things are going to be very different,” Wilson said at the STAT Summit on Thursday. “The way in which we’re going to treat Duchenne muscular dystrophy, potentially cure it, is not the way in which it’s being evaluated in the clinic now.”

Wilson, the director of the gene therapy program at the University of Pennsylvania’s medical school, knows a thing or two about disappointment. In 1999, Wilson ran...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Precision Medicine, Technology
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs
Big Pharma's ROI for drug R&D saw 'welcome' rebound in 2023: report
STAT+: Why a British hospital, and not a drugmaker, is trying to get a rare disease therapy approved
STAT+: Profiting from ‘legal’ insider trading isn’t always easy
Regeneron expands in gene editing with Mammoth deal

Share This Article